[Is hepatitis B antigenemia a risk in adjuvant cytostatic treatment of breast cancer?].
One-hundred and fifteen consecutive patients with breast cancer were examined for hepatitis B. All the patients received adjuvant chemotherapy. The median age was 46 years (range 26-54 years). None of the patients were found to be HBsAg-positive. The prevalence of HbsAg was within the limits of 0-0.026 (95% confidence interval). Vaccination of patients receiving chemotherapy is not indicated. Furthermore, regular HBsAg screening among patients under 55 years cannot be recommended.
Rasmussen
D
D
Frederiksen
P L
PL
Larsen
P M
PM
Schlichting
P
P
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006511:Hepatitis B Antigens / Q000032:analysis*; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors
D000970:Antineoplastic Agents; D006511:Hepatitis B Antigens
Er hepatitis B antigenaemi en risiko ved adjuverende cytostatisk behandling for cancer mammae?